2,5-Dimethoxy-4-trifluoromethylamphetamine
![]() | |
Clinical data | |
---|---|
Other names | 2,5-Dimethoxy-4-trifluoromethylamphetamine; DOTFM |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C12H16F3NO2 |
Molar mass | 263.260 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
2,5-Dimethoxy-4-trifluoromethylamphetamine (DOTFM) is a psychedelic drug of the phenethylamine, amphetamine, and DOx. It was first synthesized in 1994 by a team at Purdue University led by David E. Nichols.[1] DOTFM is the α-methylated analogue of 2C-TFM.
It acts as an agonist at the serotonin 5-HT2A and 5-HT2C receptors.[1] In drug discrimination tests in rats, DOTFM fully substituted for LSD and was slightly more potent than DOI.[1] In addition, (R)-DOTFM robustly induces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, with equivalent potency as (R)-DOI.[2] The drug is around twice as potent as 2C-TFM in animal studies.
In contrast to (R)-DOI, which has extraordinarily potent serotonin 5-HT2A receptor-mediated anti-inflammatory effects,[3][4] DOTFM shows no anti-inflammatory effects.[5] The differences between the drugs in this regard appear to be due to differences in functional selectivity at the serotonin 5-HT2A receptor.[5][2]
See also
References
- ^ a b c Nichols DE, Frescas S, Marona-Lewicka D, Huang X, Roth BL, Gudelsky GA, et al. (December 1994). "1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist". Journal of Medicinal Chemistry. 37 (25): 4346–4351. doi:10.1021/jm00051a011. PMID 7996545.
- ^ a b Flanagan TW, Foster TP, Galbato TE, Lum PY, Louie B, Song G, et al. (February 2024). "Serotonin-2 Receptor Agonists Produce Anti-inflammatory Effects through Functionally Selective Mechanisms That Involve the Suppression of Disease-Induced Arginase 1 Expression". ACS Pharmacology & Translational Science. 7 (2): 478–492. doi:10.1021/acsptsci.3c00297. PMC 10863441. PMID 38357283.
The effects of (R)-DOTFM were examined in the head-twitch response (HTR) assay. (R)-DOTFM produced a strong HTR with a potent ED 50 of 0.60 μmol/kg. These values are equivalent to (R)-DOI, as previously determined.
{{cite journal}}
: CS1 maint: overridden setting (link) - ^ Nichols DE, Johnson MW, Nichols CD (February 2017). "Psychedelics as Medicines: An Emerging New Paradigm". Clinical Pharmacology and Therapeutics. 101 (2): 209–219. doi:10.1002/cpt.557. PMID 28019026.
- ^ Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD (November 2008). "Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency". The Journal of Pharmacology and Experimental Therapeutics. 327 (2): 316–323. doi:10.1124/jpet.108.143461. PMID 18708586.
- ^ a b Flanagan TW, Billac G, Nichols CD (2022). "Differential Regulation of Inflammatory Responses Following 5-HT 2 Receptor Activation in Pulmonary Tissues". The FASEB Journal. 36 (S1). doi:10.1096/fasebj.2022.36.S1.R2617. ISSN 0892-6638.